Message #73 From:
NewsBot Date: November 17, 2006 09:39:00 AM
NYMX News Nymox Product a Tool for Smoking Cessation Efforts
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--November 16 is the American Cancer Society’s
Great American Smokeout, when smokers across the U.S. are encouraged to
butt out for the day and hopefully for good. Nymox Pharmaceutical
Corporation (NASDAQ:NYMX) offers its NicAlert™
products which allow concerned individuals the ability to perform an
on-the-spot evaluation of smoking status. NicAlert™
has been successfully used in many studies of smoking status and in
smoking cessation and harm reduction campaigns in the U.S. and in Europe
and is currently being used in a large smoking cessation study in
collaboration with g-Nostics Ltd. in the U.K.
NicAlert™ can be used with either urine or
saliva samples to provide an accurate visual read-out on a person’s
tobacco use or exposure within minutes. No instruments or special
training is required for its use. NicAlert™
Saliva, the saliva-based version of NicAlert™,
recently achieved certification with the CE Mark, permitting its sale in
the European Union. The urine-based version of NicAlert™
earlier received clearance from the U.S. Food and Drug Administration,
and also achieved European certification with the CE Mark.
NicAlert™ was recently used in a study by
researchers at the Centers for Disease Control and Prevention (CDC) (Journal
of Analytical Toxicology 2005; 29: 814-818), where NicAlert™
measurements were found to correlate well with the far more complex
laboratory testing (liquid chromatography-mass spectrometry) used in the
CDC laboratory.
Other independent peer-reviewed studies in the clinic have also found
the technology employed in NicAlert™ to be
accurate, rapid and cost-effective. One study, (Cancer Epidemiology,
Biomarkers & Prevention 2002; 11: 1123-1125) found that the results
obtained using Nymox's tobacco product exposure test had an “excellent
agreement” with state-of-the-art
sophisticated laboratory measurements but at a substantially lower cost
(over 90% less). Another study, (Nicotine & Tobacco Research 2002; 4:
305-9) found Nymox's product to be “an
inexpensive and rapid method to routinely biochemically confirm smoking
status at a clinical visit.”
Cigarette smoking is the single most preventable cause of premature
death in the United States. Each year, over 400,000 people die as a
result of tobacco use and exposure in the U.S. alone. Smoking is of
particular concern for pregnant women. Smoking during pregnancy is known
to increase the risk of pregnancy complications, premature delivery,
low-birth-weight infants, stillbirth, and sudden infant death syndrome
(SIDS).
This press release contains certain “forward-looking
statements” as defined in the United States
Private Securities Litigation Reform Act of 1995 that involve a number
of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future
events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.
